9.57

6.57% 0.59

Replimune Group Inc (REPL)

Overview News Price History Option Chain Financials Discussions Forecast

Replimune Group Inc stock is traded at $9.57, with a volume of 2.32M. It is up +6.57% in the last 24 hours and down -4.40% over the past month. Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Previous Close:

$8.98

Open:

$9.28

24h Volume:

2.32M

Relative Volume:

2.20

Market Cap:

$737.75M

Revenue:

Net Income/Loss:

$-209.96M

P/E Ratio:

-3.0285

EPS:

-3.16

Net Cash Flow:

$-176.27M

1W Performance:

+14.61%

1M Performance:

-4.40%

6M Performance:

-29.37%

1Y Performance:

+81.59%

1-Day Range:

$9.21

$10.16

1-Week Range:

$8.25

$10.16

52-Week Range:

$4.93

$17.00

Replimune Group Inc Stock (REPL) Company Profile

Name

Replimune Group Inc

Sector

Healthcare (1166)

Industry

Biotechnology (665)

Phone

(781) 222-9600

Address

500 UNICORN PARK, WOBURN, MA

Employee

479

Twitter

@Replimune

Next Earnings Date

2025-02-11

Latest SEC Filings

REPL's Discussions on Twitter

Compare REPL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REPL Replimune Group Inc	9.57	649.07M	0	-209.96M	-176.27M	-3.16
ONC Beone Medicines Ltd Adr	245.93	25.76B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	445.43	114.53B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.415	40.54M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	84.10	6.44B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.81	65.13B	14.09B	4.50B	2.96B	39.28

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-28-24	Initiated	ROTH MKM	Buy
Apr-17-23	Resumed	Piper Sandler	Overweight
Nov-19-21	Initiated	Piper Sandler	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-17-20	Initiated	BTIG Research	Buy
Nov-02-20	Initiated	Jefferies	Buy
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-05-20	Initiated	Barclays	Overweight
Sep-04-19	Initiated	ROTH Capital	Buy
Jul-23-19	Initiated	Chardan Capital Markets	Buy
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-08-19	Initiated	H.C. Wainwright	Buy
Apr-25-19	Initiated	Wedbush	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	JP Morgan	Overweight
Aug-14-18	Initiated	Leerink Partners	Outperform

View All

Replimune Group Inc Stock (REPL) Latest News

02:50 AM

Replimune Group (NASDAQ:REPL) Price Target Raised to $22.00 at Piper Sandler - Defense World

02:50 AM

Jun 02, 2025

Piper Sandler raises Replimune stock price target after updates - Investing.com Australia

Jun 02, 2025

Does Replimune Group Inc (NASDAQ: REPL) Still Need To Convince Analysts? - Stocksregister

Jun 02, 2025

Replimune Group (REPL) Price Target Raised by Piper Sandler Analyst | REPL Stock News - GuruFocus

Jun 02, 2025

Piper Sandler raises Replimune stock price target after updates By Investing.com - Investing.com India

Jun 02, 2025

Replimune (REPL) Price Target Raised by Piper Sandler Amid Positive Developments | REPL Stock News - GuruFocus

Jun 02, 2025

BNP Paribas Financial Markets Trims Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 02, 2025

Jun 01, 2025

Replimune (REPL) Highlights Promising RP1 Data at ASCO 2025 | REPL Stock News - GuruFocus

Jun 01, 2025

Replimune Presents New Analyses from the IGNYTE Study of RP1 plu - GuruFocus

Jun 01, 2025

Replimune Reports Promising Clinical Data for RP1 Plus Nivolumab at ASCO 2025, Highlighting Robust Responses and Safety Profile - Nasdaq

Jun 01, 2025

Replimune Presents New Analyses From The IGNYTE Study Of RP1 Plus Nivolumab In Anti-PD1 Failed Melanoma At The 2025 American Society Of Clinical Oncology (ASCO) Annual Meeting - marketscreener.com

Jun 01, 2025

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed ... - Enidnews.com

Jun 01, 2025

Replimune's RP1 Achieves 33% Response Rate in Anti-PD1 Failed Melanoma Trial | REPL Stock News - Stock Titan

Jun 01, 2025

ProShare Advisors LLC Grows Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jun 01, 2025

Replimune Group (NASDAQ:REPL) Trading Down 5.9% – Time to Sell? - Defense World

Jun 01, 2025

May 31, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Buy” from Analysts - Defense World

May 31, 2025

May 29, 2025

Replimune to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC - Defense World

May 29, 2025

May 28, 2025

Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review - Investing.com India

May 24, 2025

Barclays Remains a Buy on Replimune Group (REPL) - The Globe and Mail

May 24, 2025

May 23, 2025

Replimune director sells $260,168 in common stock By Investing.com - Investing.com South Africa

May 23, 2025

Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript - Insider Monkey

May 23, 2025

Replimune (REPL) Plans Major Stock Sale with 25.1M Shares Offeri - GuruFocus

May 23, 2025

Replimune Group Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - marketscreener.com

May 23, 2025

Replimune (REPL) Announces $250 Million Securities Shelf Filing | REPL Stock News - GuruFocus

May 23, 2025